TICKERNERD
Menu
ADMAADMAHealthcare · Biotechnology

ADMA Stock Forecast: ADMA Biologics, Inc. Price Predictions for 2026-2027

Last close, 8 Sept 2026
$9.54
−0.83% on the day

The 5 Wall Street analysts covering ADMA Biologics, Inc. hold a median 12-month price target of $17 — +78.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 7 Sept 2026 — in the lower half.

Market cap
$2.2B
Ticker Nerd rank
41 / 100
Median analyst target
$17
Analysts covering
5
Revenue$124.4M+2.0% y/y
Operating income$52.4M
Net income$37.8M
Free cash flow$27.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.6%
1M
−3.6%
YTD
−47.7%
1Y
−41.9%
From 52W high
−53.2%
From 52W low
+25.5%
$8
$20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ADMA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ADMA Biologics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 7 Sept 2026
41 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
99
Value
99
Volatility
60
Growth
47
Revisions
42
Issuance
41
Size
35
Accruals
18
Momentum
6

Quality (99): The business earns solid, repeatable profits on what it owns.

Momentum (6): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ADMA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ADMA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20Oct 25Jan 26Apr 26Jul 26ADMAHigh $21Median $17Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
4 Buy1 Hold0 Sell
Low $12Median $17High $21

The green dot is the last close — the median target sits +78.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
15 July 2026MizuhoMaintainsOutperform$20 → $17
7 May 2026Canaccord GenuityMaintainsBuy$21 → $18
7 May 2026Canaccord GenuityMaintainsBuy—
7 May 2026MizuhoMaintainsOutperform$24 → $20
7 May 2026MizuhoMaintainsOutperform—
21 Apr 2026Canaccord GenuityInitiatesBuy—
13 Apr 2026MizuhoMaintainsOutperform—
26 Mar 2026Cantor FitzgeraldDowngradeNeutral—
8 May 2025Raymond JamesMaintainsStrong Buy—
4 Mar 2025Cantor FitzgeraldReiteratesOverweight—
8 Nov 2024HC Wainwright & Co.MaintainsBuy—
8 Nov 2024Raymond JamesMaintainsStrong Buy—
14 Oct 2024HC Wainwright & Co.ReiteratesBuy—
20 Sept 2024Cantor FitzgeraldReiteratesOverweight—
12 Aug 2024HC Wainwright & Co.MaintainsBuy—
9 Aug 2024Cantor FitzgeraldMaintainsOverweight—
9 July 2024Cantor FitzgeraldMaintainsOverweight—
20 June 2024MizuhoMaintainsBuy—
10 May 2024Cantor FitzgeraldMaintainsOverweight—
10 May 2024HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ADMA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ADMA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Sept 2026, ADMA Biologics, Inc. returned −41.9% against +19.4% for the S&P 500, dividends included.

ADMA vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26ADMAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ADMA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−4.0%
Analysts raising
0
Analysts cutting
3
Fundamentals

ADMA Biologics, Inc. (ADMA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
13.6×

Cheaper than 49% of US stocks

Price / sales
4.2×

Cheaper than 30% of US stocks

Price / book
5.3×

Cheaper than 20% of US stocks

EV / EBITDA
195.8×

Cheaper than 1% of US stocks

Growth & margins
Revenue growth (YoY)
15.9%

Higher than 64% of US stocks

Earnings growth (YoY)
2.0%

Higher than 38% of US stocks

Gross margin
69.4%

Higher than 82% of US stocks

Operating margin
−123.4%

Higher than 13% of US stocks

Net margin
33.0%

Higher than 91% of US stocks

Returns & dividend
Return on equity
41.9%

Higher than 91% of US stocks

Return on assets
21.8%

Higher than 99% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

ADMA Biologics, Inc. (ADMA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • ADMA Biologics, Inc. has a market value of $2.2B and an enterprise value of $43.9B.

  • Revenue in the twelve months to 30 June 2026: $512.3M. The latest quarter grew 15.9% year on year.

  • Net income over the same four quarters: $169.0M, a 33.0% net margin.

  • Diluted earnings per share, trailing twelve months: $0.70.

  • Free cash flow in the twelve months to 30 June 2026: $116.2M.

  • ADMA Biologics, Inc. spent $187.2M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 225.4M.

  • Trailing P/E: 13.6×; forward P/E: 9.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • ADMA Biologics, Inc. employs 640 people — $800K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Sept 2026

Data provided by Twelve Data

Peers

ADMA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ADMAADMA Biologics, Inc.$2.2B
41
URGNUroGen Pharma Ltd.$2.1B
77
AUPHAurinia Pharmaceuticals, Inc.$2.1B
92
KODKodiak Sciences, Inc.$2.1B
45
RAPPRapport Therapeutics, Inc.$2.1B
45
GENBGenerate Biomedicines, Inc.$2.1B
0
ZYMEZymeworks, Inc.$2.1B
79

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own ADMA Biologics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ADMA news & analysis

Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?

Zacks Investment Research · 8 Sept 2026neutral

Zacks Investment Research published an article examining whether Wall Street brokerage recommendations, which currently view Adma Biologics (ADMA) as a good investment, are reliable guides for investors. The piece questions how much these sell-side analyst rating changes actually matter for a stock's performance.

Why it matters — ADMA watchers would care because the article evaluates the credibility of the broker ratings behind investor sentiment toward the stock.

Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)

PRNewsWire · 8 Sept 2026negative

Plaintiffs' law firm Berger Montague PC announced an investigation into potential breaches of fiduciary duty by the Board of Directors of ADMA Biologics, Inc. The investigation was announced via a press release dated Sept. 8, 2026.

Why it matters — An investigation into the board for potential fiduciary breaches could raise governance concerns for ADMA shareholders and those watching the company.

Adma Biologics (ADMA) Down 4.8% Since Last Earnings Report: Can It Rebound?

Zacks Investment Research · 4 Sept 2026neutral

Adma Biologics reported earnings 30 days ago, and its stock has declined 4.8% since that report. The article examines whether the stock can rebound following that post-earnings dip.

Why it matters — The article addresses current stock movement following the recent earnings report, which is directly relevant to ADMA shareholders tracking performance since the company's latest results.

Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)

PRNewsWire · 31 Aug 2026negative

Law firm Berger Montague PC announced an investigation into potential breaches of fiduciary duty by ADMA Biologics' Board of Directors. The probe focuses on whether the company engaged in channel-stuffing to drive revenue growth despite declining demand for its flagship product, ASCENIV.

Why it matters — ADMA watchers would care because the investigation raises concerns about the company's revenue practices and board conduct regarding its key product.

ADMA BIOLOGICS, INC. (ADMA) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty

Newsfile Corp · 26 Aug 2026negative

Bernstein Liebhard LLP announced an investigation into potential breaches of fiduciary duty by certain directors and officers of ADMA Biologics, Inc. The law firm is examining whether the company's leadership fulfilled its obligations to shareholders and whether legal remedies may be available.

Why it matters — ADMA watchers would care because the shareholder investigation raises questions about the conduct of the company's leadership and could lead to legal action.

FAQ

Frequently asked questions about ADMA stock

What is the ADMA stock price forecast for 2026-2027?

The 5 Wall Street analysts covering ADMA Biologics, Inc. have a median 12-month price target of $17, with estimates ranging from $12 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ADMA stock a buy right now?

Of the 5 analysts covering ADMA Biologics, Inc., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ADMA Biologics, Inc. 41 out of 100 across roughly 4,600 US stocks as at 7 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ADMA?

As at 7 Sept 2026, ADMA Biologics, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (99 of 100).

Will ADMA stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +78.2% from the last close, and Ticker Nerd's factor model ranks ADMA Biologics, Inc. 41 out of 100 as at 7 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ADMA stock forecast for 2030?

No analyst covering ADMA Biologics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ADMA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $21 over the next 12 months.

How has ADMA stock performed over the past year?

ADMA Biologics, Inc. returned -41.9% over the 12 months to 8 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ADMA Biologics, Inc. do?

ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and commercializing specialty plasma-derived biologics for patients with immune deficiencies and certain infectious diseases.

What is the latest news on ADMA?

The most recent item we track (Zacks Investment Research, 8 Sept 2026): "Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?". Zacks Investment Research published an article examining whether Wall Street brokerage recommendations, which currently view Adma Biologics (ADMA) as a good investment, are reliable guides for investors. The piece questions how much these sell-side analyst rating changes actually matter for a stock's performance.

Company

About ADMA Biologics, Inc.

ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and commercializing specialty plasma-derived biologics for patients with immune deficiencies and certain infectious diseases. ADMA’s current portfolio includes FDA-approved immune globulin and hyperimmune products used to help treat primary humoral immunodeficiency, support immune-compromised patients, and provide protection in hepatitis B exposure settings. The company operates an integrated model that combines plasma collection, fractionation, purification, and commercialization, allowing it to support the supply of its therapies through its own manufacturing infrastructure. ADMA serves healthcare providers and patients in the United States and internationally, with a business centered on plasma-derived therapeutics and targeted immunology applications. Headquartered in Ramsey, New Jersey, ADMA Biologics plays a specialized role in the plasma medicines market by supplying niche biologic treatments for clinical use.

CEO Mr. Adam S. Grossman · 640 employees · United States · https://www.admabiologics.com